A multicenter phase Ⅱ study of osimertinib plus infliximab in patients with EGFR-mutated non-small cell lung cancer positive for TP53 gain-of-function mutation who developed resistance to osimertinib (REGAIN trial)
A multicenter phase Ⅱ study of osimertinib plus infliximab in patients with EGFR-mutated non-small cell lung cancer positive for TP53 gain-of-function mutation who developed resistance to osimertinib (REGAIN trial). // International Journal of Lung Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S3117504X26000665?dgcid=rss_sd_all
A multicenter phase Ⅱ study of osimertinib plus infliximab in patients with EGFR-mutated non-small cell lung cancer positive for TP53 gain-of-function mutation who developed resistance to osimertinib (REGAIN trial). International Journal of Lung Cancer. https://www.sciencedirect.com/science/article/pii/S3117504X26000665?dgcid=rss_sd_all
“A multicenter phase Ⅱ study of osimertinib plus infliximab in patients with EGFR-mutated non-small cell lung cancer positive for TP53 gain-of-function mutation who developed resistance to osimertinib (REGAIN trial).” International Journal of Lung Cancer.
@article{article49821,
title = {A multicenter phase Ⅱ study of osimertinib plus infliximab in patients with EGFR-mutated non-small cell lung cancer positive for TP53 gain-of-function mutation who developed resistance to osimertinib (REGAIN trial)},
journal = {International Journal of Lung Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S3117504X26000665?dgcid=rss_sd_all}
}